A detailed history of Reynders Mc Veigh Capital Management, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Reynders Mc Veigh Capital Management, LLC holds 20,024 shares of BMY stock, worth $1.18 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
20,024
Previous 20,068 0.22%
Holding current value
$1.18 Million
Previous $833,000 24.37%
% of portfolio
0.05%
Previous 0.05%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$39.66 - $51.75 $1,745 - $2,277
-44 Reduced 0.22%
20,024 $1.04 Million
Q2 2024

Aug 13, 2024

BUY
$40.25 - $52.99 $8,975 - $11,816
223 Added 1.12%
20,068 $833,000
Q1 2024

May 07, 2024

SELL
$47.98 - $54.4 $155,887 - $176,745
-3,249 Reduced 14.07%
19,845 $1.08 Million
Q4 2023

Feb 07, 2024

SELL
$48.48 - $57.85 $98,850 - $117,956
-2,039 Reduced 8.11%
23,094 $1.19 Million
Q3 2023

Nov 09, 2023

SELL
$57.89 - $64.73 $10,478 - $11,716
-181 Reduced 0.72%
25,133 $1.46 Million
Q2 2023

Aug 09, 2023

BUY
$63.71 - $70.74 $38,226 - $42,444
600 Added 2.43%
25,314 $1.62 Million
Q1 2023

May 03, 2023

SELL
$65.71 - $74.53 $50,990 - $57,835
-776 Reduced 3.04%
24,714 $1.71 Million
Q4 2022

Feb 10, 2023

SELL
$68.48 - $81.09 $684 - $810
-10 Reduced 0.04%
25,490 $1.83 Million
Q3 2022

Nov 08, 2022

SELL
$0.13 - $76.84 $176 - $104,502
-1,360 Reduced 5.06%
25,500 $1.81 Million
Q2 2022

Aug 05, 2022

BUY
$72.62 - $79.98 $315,606 - $347,593
4,346 Added 19.3%
26,860 $2.07 Million
Q1 2022

May 11, 2022

SELL
$61.48 - $73.72 $6,762 - $8,109
-110 Reduced 0.49%
22,514 $1.64 Million
Q4 2021

Feb 11, 2022

SELL
$53.63 - $62.52 $36,092 - $42,075
-673 Reduced 2.89%
22,624 $1.41 Million
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $212,124 - $248,476
-3,585 Reduced 13.34%
23,297 $1.38 Million
Q2 2021

Aug 12, 2021

SELL
$61.91 - $67.42 $107,104 - $116,636
-1,730 Reduced 6.05%
26,882 $1.8 Million
Q1 2021

May 07, 2021

SELL
$59.34 - $66.74 $105,565 - $118,730
-1,779 Reduced 5.85%
28,612 $1.81 Million
Q4 2020

Feb 10, 2021

SELL
$57.74 - $65.43 $160,228 - $181,568
-2,775 Reduced 8.37%
30,391 $1.89 Million
Q3 2020

Oct 28, 2020

SELL
$57.43 - $63.64 $206,231 - $228,531
-3,591 Reduced 9.77%
33,166 $2 Million
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $418,550 - $489,327
7,635 Added 26.22%
36,757 $2.16 Million
Q1 2020

May 13, 2020

SELL
$46.4 - $67.43 $91,964 - $133,646
-1,982 Reduced 6.37%
29,122 $1.62 Million
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $232,123 - $302,784
4,717 Added 17.88%
31,104 $2 Million
Q3 2019

Nov 08, 2019

BUY
$42.77 - $50.71 $97,943 - $116,125
2,290 Added 9.5%
26,387 $1.34 Million
Q2 2019

Aug 06, 2019

SELL
$44.62 - $49.34 $51,982 - $57,481
-1,165 Reduced 4.61%
24,097 $1.09 Million
Q1 2019

May 10, 2019

SELL
$45.12 - $53.8 $62,581 - $74,620
-1,387 Reduced 5.2%
25,262 $1.21 Million
Q4 2018

Feb 14, 2019

SELL
$48.76 - $63.23 $31,694 - $41,099
-650 Reduced 2.38%
26,649 $1.39 Million
Q3 2018

Nov 26, 2018

SELL
$55.19 - $62.25 $13,245 - $14,940
-240 Reduced 0.87%
27,299 $1.7 Million
Q2 2018

Aug 09, 2018

SELL
$50.53 - $62.98 $31,278 - $38,984
-619 Reduced 2.2%
27,539 $1.52 Million
Q1 2018

Jul 26, 2018

BUY
$59.92 - $68.98 $1.58 Million - $1.82 Million
26,377 Added 1481.02%
28,158 $1.78 Million
Q1 2018

May 03, 2018

SELL
$59.92 - $68.98 $1.57 Million - $1.81 Million
-26,196 Reduced 93.63%
1,781 $28.2 Million
Q4 2017

Feb 06, 2018

SELL
$59.94 - $65.35 $47,592 - $51,887
-794 Reduced 2.76%
27,977 $0
Q3 2017

Nov 09, 2017

BUY
$55.23 - $63.74 $16,845 - $19,440
305 Added 1.07%
28,771 $1.83 Million
Q2 2017

Aug 14, 2017

BUY
N/A
28,466
28,466 $1.59 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Reynders Mc Veigh Capital Management, LLC Portfolio

Follow Reynders Mc Veigh Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Reynders Mc Veigh Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Reynders Mc Veigh Capital Management, LLC with notifications on news.